Literature DB >> 26637406

The regulation of function, growth and survival of GLP-1-producing L-cells.

Rune E Kuhre1, Jens J Holst1, Camilla Kappe2.   

Abstract

Glucagon-like peptide-1 (GLP-1) is a peptide hormone, released from intestinal L-cells in response to hormonal, neural and nutrient stimuli. In addition to potentiation of meal-stimulated insulin secretion, GLP-1 signalling exerts numerous pleiotropic effects on various tissues, regulating energy absorption and disposal, as well as cell proliferation and survival. In Type 2 Diabetes (T2D) reduced plasma levels of GLP-1 have been observed, and plasma levels of GLP-1, as well as reduced numbers of GLP-1 producing cells, have been correlated to obesity and insulin resistance. Increasing endogenous secretion of GLP-1 by selective targeting of the molecular mechanisms regulating secretion from the L-cell has been the focus of much recent research. An additional and promising strategy for enhancing endogenous secretion may be to increase the L-cell mass in the intestinal epithelium, but the mechanisms that regulate the growth, survival and function of these cells are largely unknown. We recently showed that prolonged exposure to high concentrations of the fatty acid palmitate induced lipotoxic effects, similar to those operative in insulin-producing cells, in an in vitro model of GLP-1-producing cells. The mechanisms inducing this lipototoxicity involved increased production of reactive oxygen species (ROS). In this review, regulation of GLP-1-secreting cells is discussed, with a focus on the mechanisms underlying GLP-1 secretion, long-term regulation of growth, differentiation and survival under normal as well as diabetic conditions of hypernutrition.
© 2016 Authors; published by Portland Press Limited.

Entities:  

Keywords:  GLP-1; diabetes; incretin hormone

Mesh:

Substances:

Year:  2016        PMID: 26637406     DOI: 10.1042/CS20150154

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  13 in total

1.  Ursolic acid activates the TGR5 receptor to enhance GLP-1 secretion in type 1-like diabetic rats.

Authors:  Shih-Hsiang Lo; Yingxiao Li; Kai Chun Cheng; Chiang-Shan Niu; Juei-Tang Cheng; Ho-Shan Niu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-07-30       Impact factor: 3.000

2.  A computer model simulating human glucose absorption and metabolism in health and metabolic disease states.

Authors:  Richard J Naftalin
Journal:  F1000Res       Date:  2016-04-12

Review 3.  Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies.

Authors:  Junfeng Li; Juan Zheng; Susanne Wang; Harry K Lau; Ali Fathi; Qinghua Wang
Journal:  Front Physiol       Date:  2017-01-30       Impact factor: 4.566

4.  Elevated circulating fasting glucagon-like peptide-1 in surgical patients with aortic valve disease and diabetes.

Authors:  Camilla Krizhanovskii; Stelia Ntika; Christian Olsson; Per Eriksson; Anders Franco-Cereceda
Journal:  Diabetol Metab Syndr       Date:  2017-10-10       Impact factor: 3.320

5.  The Dietary Furocoumarin Imperatorin Increases Plasma GLP-1 Levels in Type 1-Like Diabetic Rats.

Authors:  Lin-Yu Wang; Kai-Chun Cheng; Yingxiao Li; Chiang-Shan Niu; Juei-Tang Cheng; Ho-Shan Niu
Journal:  Nutrients       Date:  2017-10-30       Impact factor: 5.717

6.  Notoginsenoside Ft1 acts as a TGR5 agonist but FXR antagonist to alleviate high fat diet-induced obesity and insulin resistance in mice.

Authors:  Lili Ding; Qiaoling Yang; Eryun Zhang; Yangmeng Wang; Siming Sun; Yingbo Yang; Tong Tian; Zhengcai Ju; Linshan Jiang; Xunjiang Wang; Zhengtao Wang; Wendong Huang; Li Yang
Journal:  Acta Pharm Sin B       Date:  2021-03-30       Impact factor: 11.413

7.  Vertical sleeve gastrectomy activates GPBAR-1/TGR5 to sustain weight loss, improve fatty liver, and remit insulin resistance in mice.

Authors:  Lili Ding; Kyle M Sousa; Lihua Jin; Bingning Dong; Byung-Wook Kim; Ricardo Ramirez; Zhenzhou Xiao; Ying Gu; Qiaoling Yang; Jie Wang; Donna Yu; Alessio Pigazzi; Dustin Schones; Li Yang; David Moore; Zhengtao Wang; Wendong Huang
Journal:  Hepatology       Date:  2016-07-25       Impact factor: 17.425

8.  Development of betulinic acid as an agonist of TGR5 receptor using a new in vitro assay.

Authors:  Shih-Hsiang Lo; Kai-Chung Cheng; Ying-Xiao Li; Chin-Hong Chang; Juei-Tang Cheng; Kung-Shing Lee
Journal:  Drug Des Devel Ther       Date:  2016-08-22       Impact factor: 4.162

9.  Investigation of triamterene as an inhibitor of the TGR5 receptor: identification in cells and animals.

Authors:  Yingxiao Li; Kai Chun Cheng; Chiang-Shan Niu; Shih-Hsiang Lo; Juei-Tang Cheng; Ho-Shan Niu
Journal:  Drug Des Devel Ther       Date:  2017-04-05       Impact factor: 4.162

10.  On the relationship between glucose absorption and glucose-stimulated secretion of GLP-1, neurotensin, and PYY from different intestinal segments in the rat.

Authors:  Rune E Kuhre; Charlotte B Christiansen; Monika Y Saltiel; Nicolai J Wewer Albrechtsen; Jens J Holst
Journal:  Physiol Rep       Date:  2017-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.